Skip to content

Effect of patient-controlled intravenous analgesia with oxycodone and sufentanil without background dose on postoperative analgesia and immune function after endoscopic pulmonary wedge resection

Effect of patient-controlled intravenous analgesia with oxycodone and sufentanil without background dose on postoperative analgesia and immune function after endoscopic pulmonary wedge resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067466
Enrollment
Unknown
Registered
2023-01-09
Start date
2023-01-16
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Changes of postoperative immune function and postoperative pain

Interventions

Group SF:Use sufentanil to configure analgesia pump
Group OC:Use oxycodone to configure analgesia pump

Sponsors

Quanzhou First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. Patients who plan to undergo endoscopic lung wedge resection under general anesthesia of tracheal intubation; b. Age 18-65, regardless of gender; c. Body mass index (BMI): 18.5-28; d. American Society of Anesthesiologists (ASA): I-III; e. Subjects voluntarily participated in the trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: a. Subjects explicitly refused to participate in this study; b. Allergies to opioids and drug excipients; c. Use barbiturates, sedative hypnotics, phenothiazines, antipsychotics, antidepressants, rifampicin, voriconazole, antihypertensive drugs, etc; D. Suspected of abuse of narcotic analgesics or sedatives and alcoholics; e. Have a history of serious heart, brain, lung, liver, kidney or metabolic diseases (such as hypothyroidism), a history of mental illness, and a history of myasthenia gravis; f. ECG: heart rate100 times/min or serious arrhythmia; Echocardiography showed: EF value<50%; g. Acute respiratory tract infection within two weeks without cure; h. Pregnant and lactating women; i. Subjects who are considered unsuitable by other researchers to participate in this study.

Design outcomes

Primary

MeasureTime frame
Static VAS score;Dynamic VAS score;Whole blood T-lymphocyte subsets CD4+;Whole blood T-lymphocyte subsets CD8+;Percentage of NK cells;IL-2;

Secondary

MeasureTime frame
Recovery analgesia rate within 48 hours;48h dosage;Number of press and invalid press within 48 hours;Respiratory depression;Delayed awakening;Incidence rate of other side effects;

Countries

China

Contacts

Public ContactWenqin Xie

Quanzhou First Hospital Affiliated to Fujian Medical University

leonkillua@163.com13599269966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026